PharmX Technologies Limited

ASX:PHX Stock Report

Market Cap: AU$43.7m

PharmX Technologies Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for PharmX Technologies.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Software earnings growth28.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?

Feb 12
What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?

A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)

Jul 12
A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)

At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?

May 11
At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?

Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?

Nov 12
Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?

At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Apr 29
At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 02
Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Dec 13
Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PharmX Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:PHX - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20248023N/A
3/31/20247057N/A
12/31/202360911N/A
9/30/202360811N/A
6/30/20236-1811N/A
12/31/20222-1-13N/A
9/30/20224-1-13N/A
6/30/202250-13N/A
3/31/2022120-13N/A
12/31/2021120-13N/A
9/30/2021121-13N/A
6/30/2021121-13N/A
3/31/2021121-13N/A
12/31/2020111-12N/A
9/30/2020111-21N/A
6/30/2020110-30N/A
3/31/202011-1-30N/A
12/31/201910-2-30N/A
9/30/201911-3-31N/A
6/30/201911-4-21N/A
3/31/201912-3-12N/A
12/31/201812-2-13N/A
9/30/201812-1-21N/A
6/30/2018130-30N/A
3/31/201813-3N/A0N/A
12/31/201714-6N/A0N/A
9/30/201714-6N/A0N/A
6/30/201715-6N/A0N/A
3/31/201715-3N/A-1N/A
12/31/2016161N/A-1N/A
9/30/2016160N/A-1N/A
6/30/2016170N/A-1N/A
3/31/2016171N/AN/AN/A
12/31/2015171N/A2N/A
9/30/2015183N/A3N/A
6/30/2015185N/A4N/A
3/31/2015185N/AN/AN/A
12/31/2014185N/A5N/A
9/30/2014195N/A5N/A
6/30/2014194N/A6N/A
3/31/2014195N/A6N/A
12/31/2013195N/A6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PHX's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if PHX's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if PHX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if PHX's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if PHX's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PHX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 22:10
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmX Technologies Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caleb WengPAC Partners Securities Pty. Ltd.